IS3S:F:F- (EUR)

ETF | Others |

Last Closing

USD 42.525

Change

-0.22 (-0.50)%

Market Cap

N/A

Volume

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-28 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.14 (-0.27%)

USD 128.40B
SXR8:F iShares Core S&P 500 UCITS ETF..

-3.92 (-0.70%)

USD 114.04B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 108.41B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 52.77B
SXRZ:F iShares VII PLC - iShares Nikk..

-0.70 (-0.30%)

USD 52.44B
VUSA:F Vanguard Funds Public Limited ..

-0.74 (-0.74%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 46.87B
0ZC:F Zscaler Inc

+0.35 (+0.16%)

USD 37.92B
BSND:F Danone SA

-0.10 (-0.68%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

-0.74 (-0.58%)

USD 24.77B

ETFs Containing IS3S:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.47% 69% C- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.47% 69% C- 61% D-
Trailing 12 Months  
Capital Gain 8.07% 65% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.07% 63% D 56% F
Trailing 5 Years  
Capital Gain 74.18% 71% C- 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.18% 71% C- 52% F
Average Annual (5 Year Horizon)  
Capital Gain 12.56% 81% B- 71% C-
Dividend Return 12.56% 78% C+ 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.05% 60% D- 89% A-
Risk Adjusted Return 113.64% 97% N/A 96% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike